SM&A

SMA Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutics for respiratory and inflammatory disorders. Formerly known as Axikin Pharmaceuticals, the company specializes in targeting chemokine and cytokine signaling pathways to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF). Its research focuses on small molecule kinase inhibitors, including 3,5-diaminopyrazole derivatives, designed to modulate airway inflammation. The company has been led by industry veterans with extensive experience in respiratory drug discovery and has presented its findings at major international medical conferences. SMA Therapeutics aims to address significant unmet needs in pulmonary medicine through its targeted therapeutic approach.